tiotropium bromide inhalation (VR410) / Pulmatrix - LARVOL DELTA

Pulmatrix to report clinical data on PUR0200 in patients with chronic obstructive pulmonary disease (PRNewswire) - "Pulmatrix...will report data from a Phase 1B study evaluating PUR0200...on September 29th at the 2015 European Respiratory Society Congress. PUR0200 is being developed under the PK bio-equivalence pathway in Europe."

Anticipated P1 data • Chronic Obstructive Pulmonary Disease

Particle Size and Gastrointestinal Absorption Influence Tiotropium Pharmacokinetics: A Pilot Bioequivalence Study of PUR0200 and Spiriva HandiHaler. (PubMed, Br J Clin Pharmacol) - "Pharmacokinetic bioequivalence indicative of lung deposition and efficacy can be achieved by matching the reference product ISM. Due to reduced oral deposition and more efficient lung delivery, PUR0200 results in a lower AUC than Spiriva HH due to reduced absorption of drug from the gastrointestinal tract."

Journal • PK/PD data

The pharmacokinetics, pharmacodynamics and tolerability of PUR0200, a novel tiotropium formulation, in chronic obstructive pulmonary disease. (PubMed, Br J Clin Pharmacol) - "PUR0200 treatment caused bronchodilation in COPD patients that was similar in magnitude to tiotropium HH. This enabled a similar clinical effect on lung function to be achieved with PUR0200 using a lower metered dose of tiotropium compared to tiotropium HH."

Journal • PK/PD data